Review decision date: July 2014
We checked this guideline and decided that it should be updated. For details, see the update decision and the process for deciding if an update is needed. Details of the update have been published on this page. This guideline will be checked again for update at its scheduled time point according to the methods described in the guidelines manual.
Next review date: 2018
This clinical guideline offers evidence-based advice on the effective management of lower urinary tract symptoms (LUTS) in men. The lower urinary tract consists of the bladder, prostate gland and urethra (the tube that carries urine from the bladder to the end of the penis).
This guideline was previously called lower urinary tract symptoms: the management of lower urinary tract symptoms in men.
A recommendation on phosphodiesterase-5 inhibitors has been added to section 1.4 on drug treatment. A research recommendation on phosphodiesterase-5 inhibitors has been added to section 2.5. The addendum contains details of the methods and evidence used to develop these recommendations.
This guideline updates and replaces:
- Interventional procedure guidance 15
- Interventional procedure guidance 120
- Interventional procedure guidance 224
- Interventional procedure guidance 256
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The application of the recommendations in this guideline is not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.